[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN: Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist; 2010;15(3):293-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals.
  • PBL has a poor prognosis, but prognostic factors in patients who have received chemotherapy have not been adequately evaluated.
  • Seventy cases with HIV-associated PBL that received chemotherapy were identified.
  • In a univariate analysis, early clinical stage and a complete response to chemotherapy were associated with longer survival.
  • Prognosis is strongly associated with achieving a complete clinical response to CHOP or CHOP-like chemotherapy.
  • Further research is needed to improve responses using novel therapeutic agents and strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / virology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(3):194 [10942339.001]
  • [Cites] J Hematol Oncol. 2009;2:47 [19909553.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1582-4 [12824797.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Haematologica. 2007 Jan;92(1):e11-2 [17405744.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Am J Hematol. 2007 Aug;82(8):761-5 [17094093.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]
  • [Cites] Intern Med. 2009;48(7):559-62 [19336959.001]
  • [Cites] Eur J Haematol. 2009 Jun;82(6):490-2 [19220417.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]
  • [Cites] AIDS. 2009 Sep 24;23(15):2029-37 [19531926.001]
  • [Cites] Am J Clin Pathol. 2009 Oct;132(4):597-605 [19762538.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • (PMID = 20167839.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC3227958
  •  go-up   go-down


2. Soussain C, Hoang-Xuan K, Levy V: [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bull Cancer; 2004 Feb;91(2):189-92
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
  • [Transliterated title] Chimiothérapie intensive avec support hématopoïétique chez 22 patients ayant un lymphome primitif du système nerveux central ou un lymphome intraoculaire réfractaire ou en rechute: mise à jour des résultats.
  • Rescue therapies for relapsing/refractory primary central nervous system lymphoma (PCNSL) and intraocular lymphoma (IOL) remain a challenging problem for clinicians.
  • In 2001, we published encouraging results for 22 patients treated at relapse with a CYVE regimen combining high doses of Ara-C (50 mg/m(2)/d in 12 hours infusion dl through d5; 2 g/m(2)/d d2 through d5) and VP16 (200 mg/m(2)/d d2 through d5), followed by intensive chemotherapy based on high doses of thiotepa (250 mg/m(2)/d d-9 through d-7), busulfan (10 mg/kg total dose d-6 through d-4) and cyclophosphamide (60 mg/kg/d, d-3 and d-2 with hematopoietic cell rescue at d0.
  • CYVE rescue was not administered to patients with refractory IOL who had previously received high doses of methotrexate and Ara-C as part of their first-line treatment.
  • Twenty patients received the intensive chemotherapy and hematopoietic cells rescue.
  • Seven patients had neurologic adverse events during the entire procedure.
  • With a median follow up of 6.2 years, the median overall survival is 91 months, and the median survival after intensive chemotherapy has not been reached.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Aged. Busulfan / administration & dosage. Busulfan / adverse effects. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Etoposide / administration & dosage. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Middle Aged. Prognosis. Recurrence. Thiotepa / administration & dosage. Thiotepa / adverse effects

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright John Libbey Eurotext 2003.
  • (PMID = 15047459.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


3. Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozawa H, Yamashita Y, Mori N: ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol; 2003 Aug;16(8):828-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
  • Pathological features and genomic basis of a rare case of ALK(+), CD30(-), CD20(-) large B-cell lymphoma were analyzed.
  • Physical examination and laboratory tests showed anemia (hemoglobin, 7.5 g/dL), mild hepatosplenomegaly, and immunoglobin G (IgG) lambda-type monoclonal gammopathy (IgG, 2782 mg/dL).
  • The lymphoma spread exclusively in extranodal sites such as bone marrow, liver, spleen, ovary, and muscle.
  • Biopsy specimens obtained from the ovary showed monomorphic proliferation of large immunoblastic cells with basophilic cytoplasm, round-shaped nuclei with a high nuclear to cytoplasmic ratio, and prominent single nucleolus.
  • Immunostaining with anti-anaplastic lymphoma kinase (ALK) antibody, ALK1, showed finely granular cytoplasmic staining pattern.
  • These cells were also positive for epithelial membrane antigen, CD4, CD19, CD38, CD138, cytoplasmic IgG, and lambda chain, but negative for CD30 (Ber-H2), CD56, CD57, and other T- and B-cell markers.
  • Southern blot analyses revealed that Ig heavy and lambda light chain genes, but not T-cell receptor (TCR) beta gene, were clonally rearranged.
  • As 2;17 translocation resulting in the fusion of clathrin heavy chain (CLTC) gene with ALK was previously reported in inflammatory myofibroblastic tumor, we performed reverse transcriptase-polymerase chain reaction and demonstrated that the lymphoma cells contained CLTC-ALK fusion transcript.
  • Under the diagnosis of ALK(+), CD30(-), CD20(-) large B-cell lymphoma, she was treated with conventional combination chemotherapies.
  • However, the lymphoma was primarily chemotherapy resistant, and the patient died 11 months after admission.
  • We consider that this case confirms the existence of ALK(+), CD30(-), CD20(-) large B-cell lymphomas proposed by Delsol et al. (16) and further provides relevant information regarding their clinicopathological features and cytogenetics.
  • [MeSH-major] Clathrin Heavy Chains / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Oncogene Proteins, Fusion. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Antigens, CD20 / metabolism. Antigens, CD30 / metabolism. Blotting, Southern. Chromosome Aberrations. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction. Spectral Karyotyping

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12920229.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Oncogene Proteins, Fusion; 114899-12-6 / Clathrin Heavy Chains; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


Advertisement
4. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhøj P, Barton SE, EuroSIDA Study Group: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood; 2001 Dec 1;98(12):3406-12
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.
  • This study was designed to assess the influence of highly active antiretroviral therapy (HAART) on non-Hodgkin lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV).
  • Within EuroSIDA, a multicenter observational cohort of more than 8500 patients from across Europe, the incidences of NHL and subtypes (Burkitt, immunoblastic, primary brain lymphoma [PBL], and other/unknown histology) were determined according to calendar time of follow-up, and for those who initiated HAART (> or =3 drugs) also time on HAART.
  • In an adjusted Cox model for patients on HAART, the latest CD4 cell count and plasma viral load were both significantly associated with diagnosis of NHL; the relative hazard was 1.39 (range, 1.14-1.69) per 50% lower CD4 cell count, and 1.51 (range, 1.21-1.88) per 1 log higher plasma viral load.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Brain Neoplasms / complications. Brain Neoplasms / epidemiology. Burkitt Lymphoma / complications. Burkitt Lymphoma / epidemiology. CD4 Lymphocyte Count. Cohort Studies. Female. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / epidemiology. Male. Prospective Studies


5. Seymour JF, Grigg AP, Szer J, Fox RM: Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer; 2002 Feb 1;94(3):585-93
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
  • BACKGROUND: Based on in vitro synergism, the combination of cytarabine (ara-C) and cisplatin is the basis of many salvage regimens for patients with aggressive non-Hodgkin lymphoma (NHL).
  • METHODS: A Phase-II study of a 96 hour continuous infusion of cisplatin with two timed-sequential couplets of fludarabine and ara-C together with granulocyte colony stimulating factor was performed in 45 patients with previously refractory, histologically aggressive or mantle cell NHL.
  • RESULTS: Patients had predominantly diffuse large cell and/or immunoblastic NHL or its variants (80%), or they had mantle cell lymphoma (18%).
  • Peripheral blood progenitor cells were mobilized adequately after the first cycle, but collections were impaired after more prolonged therapy.
  • Patients with mantle cell lymphoma were more likely to respond than patients with other histologies (88% vs. 39%, respectively; P = 0.019), although three of eight patients had relapsed rather than refractory disease.
  • The median remission duration was 4 months, with 28% of potentially eligible patients able to proceed to subsequent high dose therapy.
  • The actuarial 2 year survival rates were 20% +/- 6% overall and 50 +/- 18% for patients with mantle cell lymphoma.
  • CONCLUSIONS: Given the adverse outlook for these patients, the results are promising, particularly for patients with mantle cell lymphoma, and suggest that the addition of fludarabine as a potential biochemical modulator may enhance the activity of cisplatin and ara-C.
  • This paradigm, in which a nucleoside analogue is used to inhibit the repair of platinum/DNA adducts, also may be applicable for the treatment of patients with other types of platinum-sensitive tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Infusions, Intravenous. Male. Middle Aged. Neutropenia / chemically induced. Prognosis. Recurrence. Salvage Therapy. Thrombocytopenia / chemically induced. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10240
  • (PMID = 11857288.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Dawson MA, Schwarer AP, McLean C, Oei P, Campbell LJ, Wright E, Shortt J, Street AM: AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A. Haematologica; 2007 Jan;92(1):e11-2
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH/MYC translocation--treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A.
  • Plasmablastic lymphoma is an AIDS related lymphoma that continues to have a poor prognosis despite significant advances in the management of HIV and lymphoproliferative diseases.
  • To date molecular abnormalities have not been described in plasmablastic lymphoma, and its aggressive clinical behaviour has been difficult to understand.
  • We describe the first reported cytogenetic abnormality in plasmablastic lymphoma, an IgH/MYC translocation.
  • It is also the first description of autologous stem cell transplantation in a patient with severe haemophilia A.
  • [MeSH-major] Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Genes, myc. Gingival Neoplasms / genetics. Hemophilia A / complications. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Large-Cell, Immunoblastic / genetics. Peripheral Blood Stem Cell Transplantation. Translocation, Genetic
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / complications. Fatal Outcome. Humans. Male. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Transplantation, Autologous. Vincristine / administration & dosage


7. Schlembach PJ, Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD: Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys; 2000 Nov 1;48(4):1107-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
  • PURPOSE: To analyze the impact of involved field radiotherapy on local control, freedom from progression, and overall survival in patients with clinical Stage III-IV, intermediate grade, or large-cell immunoblastic lymphomas that responded to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based induction chemotherapy.
  • METHODS AND MATERIALS: From July 1989 through October 1996, 32 patients with clinical Stage III and 27 patients with clinical Stage IV, intermediate grade, or large-cell immunoblastic lymphomas were prospectively enrolled on two protocols at The University of Texas M. D.
  • None had previously undergone treatment for lymphoma.
  • All 59 patients received CHOP-based chemotherapy.
  • At least six cycles of chemotherapy were delivered to 92% of the patients.
  • Involved field radiotherapy (39.6-40.0 Gy in 20-22 fractions in 74% of cases) was administered to 28/59 (47%) patients beginning 3-4 weeks after chemotherapy.
  • Irradiated and nonirradiated groups were compared in terms of maximum pre-chemotherapy tumor size and University of Texas M. D.
  • Kaplan-Meier estimates of local control per patient, freedom from progression, and overall survival for the irradiated and nonirradiated groups were calculated in terms of the stage of disease and treatment delivered.
  • The Cox proportional hazards model was used to assess the prognostic significance of tumor size, tumor score, treatment delivered, and stage.
  • The median tumor size at the start of chemotherapy in irradiated patients was 4.5 cm (range: 0-15 cm) versus 3 cm (range: 0-7 cm) in nonirradiated patients (p = 0.004).
  • This benefit was due to the dramatic improvement (p = 0.0009) in local control for patients with lymphomas measuring > or =4 cm at the start of chemotherapy (5-year rates: 89% for irradiated patients versus 33% for nonirradiated patients).
  • Eleven out of 12 (92%) patients with recurrent disease at the time of their last follow-up visit were treated initially with chemotherapy alone.
  • CONCLUSION: Involved field radiotherapy improved local control and freedom from progression in patients with > or = 4 cm Stage III-IV, intermediate grade, or large-cell immunoblastic lymphomas that responded to CHOP-based induction chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Proportional Hazards Models. Prospective Studies. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11072169.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Oksenhendler E, Gerard L, Dubreuil ML, Levy Y, Matheron S, Cazals-Hatem D, Chevret S, Clauvel JP: Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Sep;39(1-2):87-95
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL).
  • The median CD4 cell count was 276 x 10(6)/l.
  • Nineteen tumors were of the Burkitt's type, 23 were large cells, 7 immunoblastic, and 3 anaplastic.
  • The Relative Dose-Intensity of the chemotherapy was 85% for doxorubicine and 87% for cyclophosphamide.
  • In conclusion, it seems that in HIV-infected patients with NHL and a CD4 cell count above 100 x 10(6)/l, high complete remission rate and prolonged survival can be achieved with the intensive LNHIV-91 regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Adult. Bleomycin / administration & dosage. Bleomycin / toxicity. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Drug Evaluation. Etoposide / administration & dosage. Etoposide / toxicity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Methotrexate / administration & dosage. Methotrexate / toxicity. Middle Aged. Prednisone / administration & dosage. Prednisone / toxicity. Recurrence. Survival Rate. Treatment Outcome. Vindesine / administration & dosage. Vindesine / toxicity

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975387.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol
  •  go-up   go-down


9. Wilder RB, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, Cox JD: Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys; 2001 Jul 1;50(3):743-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
  • PURPOSE: To analyze the results with involved-field radiotherapy after aggressive lymphomas had decreased in size by 50-99% in response to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy.
  • METHODS AND MATERIALS: From 1988 through 1996, 294 previously untreated patients with Working Formulation intermediate-grade or large-cell immunoblastic lymphomas underwent CHOP-based chemotherapy on 2 consecutive protocols at the M. D.
  • Forty-four (15%) of these patients achieved, based on international working group guidelines, a partial (50-75%) response (n = 25), or unconfirmed complete (76-99%) response (n = 19) to a median of 6 cycles of chemotherapy.
  • These patients were treated with salvage involved-field radiotherapy (n = 32) or chemotherapy (n = 12), e.g., MINE-ESHAP, without autologous stem-cell rescue (ASCR).
  • CONCLUSION: Progression-free and overall survival in aggressive lymphoma patients who underwent salvage radiotherapy were similar to results reported for high-dose chemotherapy with ASCR.
  • The role of salvage radiotherapy in partial and unconfirmed complete responders to CHOP chemotherapy justifies examination in a large, cooperative group trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / radiotherapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Methylprednisolone Hemisuccinate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prednisone / administration & dosage. Retrospective Studies. Salvage Therapy. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395243.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5GMR90S4KN / Methylprednisolone Hemisuccinate; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; NR7O1405Q9 / Mesna; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; CHOP protocol; MINE-ESHAP protocol
  •  go-up   go-down


10. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V: Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol; 2001 Feb 01;19(3):742-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
  • PURPOSE: To assess the feasibility and efficacy of intensive chemotherapy with hematopoietic stem-cell rescue (IC + HCR) in patients with refractory or recurrent primary CNS lymphoma (PCNSL) or intraocular lymphoma (IOL).
  • Intravenous clonazepam 2 mg/d was given prophylactically from the day before initiation of busulfan therapy to the day after completion of busulfan therapy.
  • Patients with refractory or recurrent PCNSL underwent IC + HCR only if they were chemosensitive to two cycles of salvage treatment with cytarabine (2 g/m(2)/d days 2 through 5 and 50 mg/m(2)/d days 1 through 5 in a 12-hour infusion) and etoposide (VP-16; 200 mg/m(2)/d days 2 through 5) (CYVE).
  • Twenty patients entered the IC + HCR program: twelve entered after CYVE treatment, seven entered directly, and one had previously been retreated with high-dose MTX.
  • Fourteen patients remained alive (median follow-up time, 41.5 months).
  • Seven patients had neurologic adverse events during the entire procedure.
  • The entire procedure seemed to be most toxic in patients > or = 60 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Central Nervous System Neoplasms / therapy. Eye Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Feasibility Studies. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / therapy. Male. Methotrexate / administration & dosage. Middle Aged. Nervous System Diseases / chemically induced. Salvage Therapy. Thiotepa / administration & dosage

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11157026.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD: Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys; 2001 Jan 1;49(1):17-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.
  • PURPOSE: To test the hypothesis that prechemotherapy tumor size affects the dose of radiation that should be delivered to intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-based induction chemotherapy.
  • METHODS AND MATERIALS: From September 1988 through December 1996, 294 patients with newly diagnosed, Stage I-IV, intermediate-grade or large-cell immunoblastic lymphomas were enrolled on 2 prospective protocols at the M. D.
  • Treatment consisted of CHOP-based chemotherapy with or without involved field radiotherapy.
  • One hundred seventy-two patients, with 178 nodal sites and 87 nonbony, extranodal sites of disease achieved a complete response to 2-6 cycles of chemotherapy and underwent involved field radiotherapy.
  • Total radiation doses ranged from 30.0 to 50.4 Gy (mean +/- standard deviation: 39.7 +/- 2.5 Gy) over 22-49 days using a daily fraction size of 1.3-2.3 Gy.
  • Because various fraction sizes were delivered, the linear-quadratic model was used to convert total radiation doses to biologically equivalent doses given at 1.8 Gy per fraction (D1.8).
  • An alpha/beta ratio of 10 Gy was used for the lymphomas, resulting in D1.8 ranging from 29.1 to 50.8 Gy.
  • Regression tree analysis was also performed on patients with nonbony disease who received D1.8 = 29.1-39.1 Gy to determine if small lymphomas could be locally controlled with relatively low doses of radiation.
  • Regression tree analysis of nodal sites identified 3 distinct groups: (a) lymphomas < or = 10 cm and D1.8 = 29.1-39.1 Gy;.
  • (b) lymphomas < or = 10 cm and D1.8 = 39.2-50.8 Gy; and (c) lymphomas > 10 cm.
  • For nonbony lymphomas that measured < 3.5 cm, low doses of radiation resulted in excellent local control (5-year rates: 96% vs. 97% for D1.8 = 29.1-39.1 Gy vs. D1.8 = 39.2-50.8 Gy; p = 0.610).
  • For 3.5-10.0 cm lymphomas, higher doses of radiation resulted in better local control (5-year rates: 40% versus 98% for D1.8 = 29.1-39.1 Gy versus D1.8 = 39.2-50.8 Gy, p < 0.0001).
  • A narrow dose range (D1.8 = 39.2-40.7 Gy) was delivered to the 8 lymphomas measuring > 10 cm that completely responded to 6 cycles of chemotherapy, resulting in a 5-year local control rate of only 70%.
  • CONCLUSION: D1.8 ranging from 29.1 to 39.1 Gy yielded excellent local control for nonbony lymphomas measuring < 3.5 cm that had completely responded to a median of 3 cycles of CHOP-based chemotherapy.
  • D1.8 ranging from 39.2 to 50.8 Gy yielded excellent local control for nonbony lymphomas measuring 3.5-10.0 cm that completely responded to either 3 or 6 cycles of chemotherapy.
  • For nonbony lymphomas measuring > 10 cm that completely responded to 6 cycles of chemotherapy, D1.8 ranging from 39.2 to 40.7 Gy yielded suboptimal local control, suggesting that higher doses of radiation are indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide. Dose-Response Relationship, Radiation. Doxorubicin. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone. Prospective Studies. Radiotherapy Dosage. Regression Analysis. Vincristine

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11163493.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D: A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Apr;37(3-4):351-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
  • The purpose of this study was to develop a model for predicting the occurrence of life-threatening neutropenia (LN, ANC < or = 0.5 x 10(9)/l) and febrile neutropenia (FN, an ANC < 0.5x10(9)/l in association with a body temperature of > or = 38.3 degrees C) after the first cycle of CHOP therapy in patients newly diagnosed with aggressive NHL.
  • One hundred and forty-five patients, aged > or = 15 years, with newly diagnosed diffuse mixed, diffuse large-cell or large-cell immunoblastic lymphoma (IWF categories, F, G, H), who had been treated with CHOP at King Chulalongkorn Memorial Hospital between June 1994 and December 1998, were entered into the study.
  • The criteria for eligibility included complete work-up for baseline evaluation, treatment with standard CHOP chemotherapy, at least one complete blood count performed during days 8-14 post-treatment or if at any time the patients experienced a BT of > or = 38.3 degrees C and were not treated with any colony-stimulating factors (CSFs).
  • Thirty-nine percent of the patients had LN at nadir and 33% developed FN after the first course of CHOP.
  • By using stepwise logistic regression analysis, the pretreatment variables independently predictive of the LN at nadir and the FN were serum albumin concentration of < or = 3.5 g/dl, serum LDH > 1 x normal and whether there was bone marrow involvement of lymphoma at presentation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fever / epidemiology. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Humans. Incidence. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Prednisone / adverse effects. Prednisone / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10752986.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Skugor ND, Perić Z, Vrhovac R, Radić-Kristo D, Kardum-Skelin I, Jaksić B: Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma. Coll Antropol; 2010 Mar;34(1):241-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
  • Relatively few cases of Epstein-Barr (EBV)-positive B-cell lymphomas arising in patients with angioimmunoblastic T-cell lymphoma (AITL) have been reported.
  • We report a case of AITL in which diffuse large B-cell lymphoma arose 13 months after the initial diagnosis of AITL.
  • The patient initially recieved FED chemotherapy (fludarabine, cyclophosphamide, dexamethasone) followed by elective autologous hematopoietic stem cell transplantation.
  • The FNAC of the enlarged cervical lymph nodes was performed again, but this time the smears were composed of polymorphous population of lymphocytes with the predomination of large cells, CD20+ on immunocytochemical stains.
  • CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) was then administered, resulting in good partial response of the disease.
  • Reduced intensity allogeneic stem cell transplantation performed thereafter, resulted in complete remission of the disease.
  • AITL is a rare lymphoproliferative disorder in which the neoplastic T-cells represent the minority of the lymph node cell population and almost all cases harbor EBV-infected B-cells.
  • Various authors postulated that immunodeficiency in AITL patients together with immunosuppressive effects of cytotoxic drugs, may be responsible for EBV-induced proliferation of latently or newly EBV-infected B-cells with eventual clonal selection and progression to aggressive B-cell lymphoma.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Fine-Needle. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Epstein-Barr Virus Infections / pathology. Female. Humans. Immunophenotyping. Neoplasm Recurrence, Local / pathology. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432757.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. Sasaki S, Shikama N, Koiwai K, Kadoya M: Relationship between the response to treatment and the prognosis of patients with aggressive lymphomas treated with chemotherapy followed by involved-field radiotherapy: radiographic assessment. Jpn J Clin Oncol; 2008 Jan;38(1):43-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between the response to treatment and the prognosis of patients with aggressive lymphomas treated with chemotherapy followed by involved-field radiotherapy: radiographic assessment.
  • OBJECTIVE: We examined the relationship between the response to treatment and prognosis of patients with aggressive lymphoma.
  • METHODS: We reviewed 33 patients with aggressive lymphoma treated with chemotherapy consisting of the CHOP regimen followed by radiotherapy.
  • After three to six cycles of chemotherapy, involved-field radiotherapy was performed.
  • We evaluated the response to treatment by computed tomography (CT), magnetic resonance imaging (MRI) and gallium scintigraphy (Ga-67) at the time of completion of chemotherapy and at the time of completion of radiation therapy.
  • RESULTS: The 2-year progression-free survival rates of the patients with Ga-67 positive uptake and Ga-67 negative uptake after completion of chemotherapy were 78 and 26% (P = 0.009), respectively.
  • However, there were no statistically significant correlations between progression-free survival and the response after completion of chemotherapy determined by CT (P = 0.75) or MRI (P = 0.19).
  • The response to treatment at the time of completion of overall treatment was not useful for prediction of prognosis.
  • CONCLUSIONS: Ga-67 positive uptake at the completion of chemotherapy before radiotherapy may be associated with poor prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gallium Radioisotopes. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18258714.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


15. Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA: Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer; 2001 Jul 15;92(2):207-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
  • BACKGROUND: To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluating dose-escalated cyclophosphamide and etoposide in the cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide (CHOPE) regimen.
  • METHODS: Eligibility criteria included histologically documented, diffuse small cleaved, diffuse mixed, diffuse large cell, or immunoblastic lymphoma, Stage III--IV or bulky Stage II disease, and an ECOG performance status of 0--1.
  • The MTD in both studies was defined as the dose at which 50% of patients had 1) Grade 4 neutropenia or thrombocytopenia lasting 7 days or more, or 2) Grade 3--4 hemorrhage or nonhematologic toxicity (excluding alopecia, nausea, and emesis), or 3) were prevented from receiving 100% of drug on Day 22.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / prevention & control. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466671.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA45418
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


16. Ko AH, Yuen AR: Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma; 2002 Sep;43(9):1789-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes associated with very late relapses in diffuse large cell lymphoma.
  • While the majority of patients achieve complete remission (CR) following treatment for diffuse intermediate-grade and immunoblastic non-Hodgkin's lymphoma, many will eventually relapse.
  • It is known that late-relapsing patients have a better prognosis than those who relapse earlier; however, the optimal choice of therapy and clinical outcomes in this former group remain uncertain.
  • We report here our experience with patients who develop a very late relapse of their disease, defined as occurring in the fifth year or later from the time of original diagnosis following a period of continuous CR.
  • The overall poor prognosis in this group of patients justifies the use of more aggressive treatment approaches in the future, such as high dose therapy with stem cell support, rather than conventional salvage chemotherapy regimens.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Adult. Aged. Databases as Topic. Disease-Free Survival. Female. Humans. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Prognosis. Recurrence. Salvage Therapy. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12685833.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner K, Chott A, Jaeger U: Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia; 2004 Jan;18(1):146-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
  • To define reproducible criteria for subgroups of diffuse large B-cell lymphomas (DLBCL), including lymphomas with plasmablastic/plasmacytoid features (PB/PC-Fs), we investigated 66 DLBCL; the samples were categorized as either centroblastic (CB), immunoblastic (IB) or PB/PC-F applying standardized morphologic criteria.
  • Most PB/PC-F were CD20+, cIgM+, MUM-1+, CD138+/-, bcl-6-, corresponding to an activated B-cell phenotype.
  • Immunoglobulin-V(H) gene mutation analysis was consistent with a germinal or postgerminal center-cell origin.
  • Importantly, PB/PC-F were resistant to standard chemotherapy (complete remission rate 47%, relapse rate 71%) and even autologous stem-cell transplantation.
  • Our data indicate a strong association of plasmablastic/plasmacytoid morphology with TP53 deletions, poor response to chemotherapy and short survival.
  • [MeSH-major] Genes, p53 / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / pathology. Plasma Cells / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / analysis. Female. Follow-Up Studies. Genes, Immunoglobulin. Germinal Center / immunology. Herpesvirus 4, Human / genetics. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Lymphoma, Large-Cell, Immunoblastic / classification. Lymphoma, Large-Cell, Immunoblastic / mortality. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Prognosis. RNA, Viral / genetics. Sequence Deletion. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14603341.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / RNA, Viral
  •  go-up   go-down


18. Villela L, López-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E: Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer; 2001 Apr 15;91(8):1557-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens.
  • BACKGROUND: The current study was conducted to analyze the outcome and prognostic factors of patients with diffuse large B-cell lymphoma (DLCL) who did not achieve a complete response (CR) to first-line treatment.
  • METHODS: The current study was comprised of 83 patients (43 males and 40 females with a median age of 62 years) who did not achieve a CR (58 of whom had primary refractory disease and 25 of whom achieved a partial response) with initial treatment (doxorubicin-containing regimens in 87% of cases) from a series of 239 patients consecutively diagnosed with DLCL at a single institution.
  • Initial variables, response to therapy, and salvage treatment were analyzed to predict survival.
  • Among the 58 patients with primary refractory disease, 18 died during initial treatment due to toxicity (14 patients) or disease progression (4 patients).
  • The main variables predicting early death were a poor PS, age > 60 years, and an immunoblastic DLCL subtype.
  • With regard to those patients achieving a partial response, 18 of the 25 patients received further therapy with 28% of them achieving a CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Health Status. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11301405.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M: A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Biotechnol Annu Rev; 2005;11:381-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
  • Non-Hodgkin's lymphoma (NHL) remains an important complication of associated HIV infection despite advances in antiretroviral therapy (ART), and the optimum chemotherapy regimen for this disease remains to be defined.
  • Patients with aggressive histology HIV-related NHL who were previously untreated with chemotherapy, and who had no active opportunistic infection were eligible for the study.
  • Chemotherapy consisted of cyclophosphamide 350 mg/m2, vincristine 2 mg, bleomycin 10 U/m2; and prednisone 100 mg q2 days x 12 weeks, with increasing doses of doxorubicin 25-50 mg/m2 and etoposide 25-50 mg/m2 intravenously and 50-100 mg/m2 orally.
  • Endpoints were determination of maximum tolerated dose of doxorubicin and etoposide, treatment tolerability, and survival.
  • Forty-seven patients were enrolled, most with diffuse large-cell or immunoblastic NHL.
  • Thirty-two cycles (4.9%) were delayed >6 days because of toxicity; 30 patients (64%) completed all 12 weeks of treatment.
  • After completion of therapy, 14 patients had a complete response (30%), and 4 had a partial response (8%).
  • Median time to progression was 9 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Bleomycin / adverse effects. Bleomycin / therapeutic use. CD4 Lymphocyte Count. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Injections, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Prospective Studies. Recombinant Proteins. Survival Analysis. Treatment Outcome. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216784.001).
  • [ISSN] 1387-2656
  • [Journal-full-title] Biotechnology annual review
  • [ISO-abbreviation] Biotechnol Annu Rev
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


20. Boulanger E, Agbalika F, Maarek O, Daniel MT, Grollet L, Molina JM, Sigaux F, Oksenhendler E: A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J; 2001;2(3):172-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
  • INTRODUCTION: Primary effusion lymphoma is a rare type of B-cell lymphoproliferative disorder which is mainly observed in patients with HIV infection.
  • Lymphomatous cells bridge features of immunoblastic and anaplastic cells with a non-B non-T phenotype and are characterized by the presence of the human herpesvirus 8 genome.
  • PATIENTS AND METHODS: : Twelve HIV-infected patients with serous effusions containing large HHV8(+) lymphomatous cells were extensively evaluated to disclose associated visceral involvement.
  • RESULTS: Extraserous localizations of lymphoma were present in six cases (50%): mediastinal (n = 2), mesenteric (n = 2), pancreatic (n = 1), and bone marrow involvement (n = 1).
  • Three patients are in complete remission at 28, 53 and 55 months after high-dose chemotherapy (n = 1), cidofovir and alpha-interferon combination therapy (n = 1), and antiretroviral therapy alone (n = 1).
  • CONCLUSION: The clinical and molecular pattern, as well as the response to therapy suggest that primary effusion lymphoma represents an heterogenous type of virus-induced B-cell lymphoproliferative disorder, sharing pathophysiological features with that induced by the Epstein-Barr virus and occurring in immunocompromised patients.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Pneumocystosis and HIV .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920242.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Organophosphorus Compounds; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8J337D1HZY / Cytosine; 8N3DW7272P / Cyclophosphamide; JIL713Q00N / cidofovir; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 37
  •  go-up   go-down


21. Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM: Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma; 2005 Dec;46(12):1721-7
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis.
  • Non-Hodgkin's lymphoma of the paranasal sinus is an uncommon presentation of extranodal lymphoma.
  • Its natural history, treatment and prognosis have been infrequently characterized in the medical literature; however, a tendency to involve the central nervous system (CNS) has been noted.
  • In British Columbia (population 4 million), a central database for lymphomas has allowed us to accurately track cases of paranasal sinus lymphoma diagnosed since 1980.
  • A retrospective review was performed on the 44 patients who presented with primary paranasal sinus lymphoma (stage I or II) between 1980 and 1999.
  • Complete diagnostic and follow-up data including stage, treatment, response rates, sites of relapse and survival data were available for all patients.
  • The types of lymphoma found were: diffuse large B cell (including immunoblastic), n = 37 (84%); T/NK nasal type, n = 3 (8%); peripheral T cell, not otherwise classified, n = 2 (4%); and others, n = 2 (4%).
  • Beginning in May 1985, intrathecal chemotherapy was added to our standard treatment plan of multi-agent chemotherapy and local irradiation.
  • Before 1985, 2 of 5 patients developed leptomeningeal metastasis.
  • Following the institution of intrathecal chemotherapy, only 8% (3 of 39) of patients have developed CNS disease.
  • Primary paranasal sinus lymphoma is an uncommon presentation of lymphoma that carries the potential risk of spreading to the leptomeninges.
  • Treatment with combined modality chemotherapy and irradiation can cure many patients and the addition of intrathecal chemotherapy may reduce the risk of CNS relapse.
  • [MeSH-major] Chemoprevention. Lymphoma, Non-Hodgkin / physiopathology. Paranasal Sinus Neoplasms / physiopathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263574.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol; 2006 Sep 1;24(25):4123-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
  • PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior AIDS, or performance status less than 2.
  • All the patients were assessable for safety and 52 were assessable for the tumor response after treatment completion.
  • Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27).
  • Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis.
  • CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Risk Factors. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e6 [17308260.001]
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e7 [17308261.001]
  • (PMID = 16896005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


23. Brousse C, Baumelou E, Morel P: Primary lymphoma of bone: a prospective study of 28 cases. Joint Bone Spine; 2000;67(5):446-51
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of bone: a prospective study of 28 cases.
  • PURPOSE: To conduct a prospective study of primary lymphoma of bone (PLB) comparatively with extraskeletal non-Hodgkin's lymphomas (ESNHLs) and secondary lymphoma of bone (SLB).
  • PATIENTS AND METHODS: The 28 cases of PLB, 2932 cases of ESNHL, and 219 cases of SLB included between April 1, 1993, and October 1, 1997, in a treatment protocol for NHL developed by the Adult Lymphoma Study Group, were studied prospectively.
  • In the PLB group, 54% of patients had diffuse large cell tumors and 11% diffuse mixed tumors; in the ESNHL group, 39% had diffuse large cell, 13% diffuse mixed, and 8% diffuse immunoblastic tumors; and in the SLB group, 45% had diffuse large cell, 10% diffuse mixed, and 12% diffuse immunoblastic tumors.
  • A complete or partial response to induction therapy was noted in 86% of PLB patients, 84% of ESNHL patients, and 78% of SLB patients.
  • Further studies are needed to determine the effect of radiation therapy at completion of the treatment protocol and to look for prognostic factors associated with bone involvement.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Surveys and Questionnaires. Survival Rate. Treatment Outcome. Vindesine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11143912.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; LNH 87 protocol
  •  go-up   go-down


24. Xu RH, Jiang WQ, Li YH, Lin TY, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ: [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases]. Zhonghua Yi Xue Za Zhi; 2003 Feb 10;83(3):191-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases].
  • OBJECTIVE: To analyze the curative effect of aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis.
  • METHODS: The curative effects of aggressive non-Hodgkin's lymphoma which were diagnosed as diffuse small cleaved (E), diffuse mixed (F), diffuse large cell (G) or diffuse immunoblastic lymphoma (H) pathologically and certified as B cell lymphoma immunohistologically and treated with CHOP or other ADM-containing regimens for at least 4 cycles from 1993 to 1997 were analyzed.
  • CONCLUSION: The treatment with CHOP as its main component has a beneficial effect on aggressive B cell lymphoma in low risk group, but is less effective for the low-intermediate, high-intermediate, and high risk.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Follow-Up Studies. Humans. Infant. Middle Aged. Prednisone / administration & dosage. Prognosis. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12812658.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


25. Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, Makimoto A, Kagami Y, Terauchi T, Matsuno Y, Tobinai K: Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol; 2007 Mar;37(3):216-23
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study.
  • BACKGROUND: The incidence of primary bone lymphoma (PBL) is so rare that many of its aspects remain unknown.
  • All patients underwent chemotherapy with half receiving radiotherapy as their initial treatment.
  • Although 19 (68%) patients had diffuse large B-cell lymphoma (DLBCL), other histopathological subtypes (three B-lymphoblastic lymphoma, two anaplastic large cell lymphoma, two indolent B-cell lymphoma, one NK/T-cell lymphoma (NTCL) and one Hodgkin lymphoma) were also included.
  • Only 'histopathological subtype (immunoblastic variant of DLBCL or NTCL versus others)' and 'response to initial treatment (progression versus remission)' were factors significantly affecting overall survival.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Hodgkin Disease / pathology. Humans. Lymphoma, B-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472971.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


26. Montalban C, Santon A, Boixeda D, Bellas C: Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut; 2001 Oct;49(4):584-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication.
  • BACKGROUND: Most low grade gastric lymphomas arising from the mucosa associated lymphoid tissue (MALT) are related to Helicobacter pylori colonisation.
  • In contrast, high grade lymphomas of the stomach, although also related to H pylori, do not usually respond to eradication treatment.
  • CASE REPORT: A 36 year old patient was referred from another hospital with a diagnosis of a low grade gastric MALT lymphoma associated with H pylori.
  • The patient was in stage I and while waiting for the biopsies to be reviewed H pylori eradication therapy was given as the first step of treatment.
  • Review of the biopsies showed a high grade immunoblastic lymphoma with areas of low grade gastric MALT lymphoma (high grade gastric MALT lymphoma or diffuse large B cell lymphoma with areas of MALT type lymphoma of the WHO classification).
  • The patient received no further treatment but has been closely followed up for 32 months with sequential endoscopies to obtain biopsies for histological studies, H pylori cultures, and polymerase chain reaction analysis of the IgH gene.
  • CONCLUSION: The response of this patient indicates the possibility that some cases of high grade gastric MALT lymphoma (possibly patients in stage I with a superficial or limited disease) may still be responsive to H pylori antigenic drive and may be cured with eradication therapy.
  • Prospective studies should be performed to identify patients with high grade gastric MALT lymphomas that may respond to eradication therapy and be spared of other more aggressive treatments.
  • [MeSH-major] Helicobacter Infections / drug therapy. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Gene Rearrangement. Humans. Male. Polymerase Chain Reaction / methods. Remission Induction

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11559658.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  • [Other-IDs] NLM/ PMC1728454
  •  go-up   go-down


27. Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR: The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol; 2004 Oct;15(10):1495-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential chemotherapy program developed to improve outcome in advanced, aggressive non-Hodgkin's lymphomas.
  • Patients with aggressive non-Hodgkin's lymphomas (working formulation: intermediate grade or immunoblastic), bulky stage I and stages II-IV, were eligible.
  • Acute and late toxicities of treatment were manageable and acceptable.
  • Toxic death on treatment was 2.4%.
  • When the diffuse large cell lymphoma histologies were grouped according to the International Prognostic Index (IPI), complete remission and OS in the low-intermediate (LI), and high-intermediate (HI) risk groups were improved by 5%-15% compared with historical CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone).
  • CONCLUSIONS: The NHL-15 program can be administered safely and effectively to achieve high rates of durable remission when used for the treatment of advanced stage, aggressive, non-Hodgkin's lymphomas.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15367410.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA05826; United States / NCI NIH HHS / CA / R01 CA61522
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


28. Hagenah GC, Wündisch T, Eckstein E, Zimmermann S, Holst F, Grimm W, Neubauer A, Lohoff M: [Sepsis-like disease in an immunocompromised patient with a travel history to Mallorca]. Internist (Berl); 2007 Jul;48(7):727-30
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue culture allowed for typing of the parasites as belonging to the L. donovani/infantum complex, DNA sequencing confirmed infection with L. infantum.
  • Surprisingly, histological examination of the resected colon reveiled the presence of an immunoblastic B-cell lymphoma.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Immunologic Deficiency Syndromes / complications. Leishmania infantum. Leishmaniasis, Visceral / diagnosis. Lymphoma, Large-Cell, Immunoblastic / diagnosis. Pancytopenia / etiology. Sepsis / etiology. Travel
  • [MeSH-minor] Adult. Animals. Azathioprine / adverse effects. Azathioprine / therapeutic use. Biopsy. Bone Marrow / pathology. Colectomy. Colitis, Ulcerative / drug therapy. Colon / pathology. Comorbidity. Desoxycorticosterone / adverse effects. Desoxycorticosterone / therapeutic use. Diagnosis, Differential. Germany. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Male. Spain

  • MedlinePlus Health Information. consumer health - Sepsis.
  • MedlinePlus Health Information. consumer health - Traveler's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1561-77 [16257344.001]
  • [Cites] J Clin Microbiol. 2006 Jul;44(7):2343-7 [16825347.001]
  • [Cites] Internist (Berl). 2006 Aug;47(8):825-8, 830-3 [16819655.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2005 Jul;24(7):471-6 [15997368.001]
  • [Cites] Microbes Infect. 2005 Oct;7(13):1370-5 [16046170.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1995 May-Jun;89(3):273-5 [7660431.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1995 Jan-Feb;89(1):33 [7747301.001]
  • [Cites] Clin Microbiol Rev. 1997 Apr;10(2):298-319 [9105756.001]
  • (PMID = 17541532.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 40GP35YQ49 / Desoxycorticosterone; MRK240IY2L / Azathioprine
  •  go-up   go-down


29. Gilaberte M, Gallardo F, Bellosillo B, Saballs P, Barranco C, Serrano S, Pujol RM: Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma. Br J Dermatol; 2005 Oct;153(4):828-32
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with human immunodeficiency virus (HIV) increases the risk of developing non-Hodgkin lymphoma.
  • Plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell lymphoma that often involves the oral cavity of HIV+ patients.
  • It is characterized by immunoblastic morphology and plasma cell phenotype.
  • We report a 44-year-old man with AIDS and Kaposi sarcoma (KS) previously treated with doxorubicin who, following treatment with highly active antiretroviral therapy, developed an erythematous infiltrated nodule on the right arm.
  • Histology showed subcutaneous fat necrosis and clusters of atypical large plasma cells (plasmablastic cells).
  • Two years later an infiltrated plaque developed on the abdominal wall.
  • PBL may be seen in patients with transplants or receiving chemotherapy, but is usually observed in patients with advanced AIDS.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / complications. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / complications
  • [MeSH-minor] Adult. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Neoplasm Regression, Spontaneous. Recurrence

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181470.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Lorusso V, Palmieri G, Bianco AR, Abate G, Catalano G, De Vita F, Dammacco F, Lauta VM, Lucarelli G, Polimeno G, Mantovani G, D'Aprile M, Marzullo F, De Lena M: CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group. Int J Oncol; 2000 Jan;16(1):149-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
  • From January 1992 to December 1995, 129 patients with previously untreated non-Hodgkin's lymphoma were randomised in a phase III multicenter trial to receive CEOP-B/VIMB or ProMACE-CytaBOM.
  • Eligibility criteria included intermediate or high grade lymphoma (follicular large cell, diffuse small cleaved-cell, diffuse mixed, diffuse large-cell and immunoblastic) with an Ann Arbor stage II bulky, III or IV.
  • At a median follow-up of 60 months there were no significant differences between the treatment response rates [82% (60%CR) for CEOP-B/VIMB vs. 81% (69% CR) for ProMACE-CytaBOM].
  • Conversely, with regard to disease-free survival, a significant difference was observed between the two treatment arms (42% for CEOP-B/VIMB vs. 24% for ProMACE-CytaBOM at 5 years; p=0.046).
  • Moreover, when response rates and outcome were analysed for different prognostic subgroups according to International Prognostic Index, no significant differences were observed between the treatment groups.
  • It is important to note that neither regimen was able to improve outcome of poor risk patients who fared badly with both treatments (median survival 9 and 8 months respectively).
  • Toxicity was also similar in both treatments with grade 3-4 leukopenia observed in 39% and 47% of cases and grade 3-4 thrombocytopenia in 24% and 27% of cases respectively.
  • In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10601560.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CEOP-B protocol; PROMACE-CytaBOM protocol
  •  go-up   go-down


31. Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill PS, Levine AM: Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res; 2002 Feb;26(2):121-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In non-Hodgkin's lymphoma, less than 20% of untreated de novo lymphomas express MDR-1 compared with approximately 50% after failure of chemotherapy.
  • We wished to study the expression of MDR-1 in AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).
  • Tissue biopsies from 50 patients with newly diagnosed AIDS-NHL were studied by immunohistochemical analysis using C494, a monoclonal antibody specific for the MDR-1 isoform of P-gp.
  • MDR-1 expression was correlated with patient demographics, lymphoma characteristics, response to chemotherapy, and survival.
  • Thirty-two patients (63%) had received prior anti-HIV therapy, including a protease inhibitor in five (10%).
  • Pathologic types consisted of diffuse large cell in 13 (26%), immunoblastic in 13 (26%), small non-cleaved in 22 (44%), and high grade not otherwise specified in two (4%).
  • Pre-treatment lymphoma tissues from 33 patients (66%) stained positively for MDR-1.
  • Strategies to overcome MDR-1 expression may be important for initial treatment in patients with AIDS-NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / metabolism. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Lymphoma, AIDS-Related / metabolism. Neoplasm Proteins / biosynthesis. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / mortality. Adult. Anti-HIV Agents / therapeutic use. Bleomycin / administration & dosage. Bleomycin / metabolism. Bleomycin / pharmacology. Cyclophosphamide / administration & dosage. Cyclophosphamide / metabolism. Cyclophosphamide / pharmacology. Dexamethasone / administration & dosage. Dexamethasone / metabolism. Dexamethasone / pharmacology. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / metabolism. Doxorubicin / pharmacology. Female. Humans. Leucovorin / administration & dosage. Leucovorin / metabolism. Leucovorin / pharmacology. Male. Methotrexate / administration & dosage. Methotrexate / metabolism. Methotrexate / pharmacology. Middle Aged. Prednisone / administration & dosage. Prednisone / metabolism. Prednisone / pharmacology. Remission Induction. Retrospective Studies. Survival Analysis. Vincristine / administration & dosage. Vincristine / metabolism. Vincristine / pharmacology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11755462.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol
  •  go-up   go-down


32. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ: Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma; 2002 Apr;43(4):767-72
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase II study was conducted to evaluate the safety and efficacy of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment in patients with Richter's syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-Hodgkin's lymphoma (NHL).
  • Histologic diagnosis was large cell NHL transformation in 15 patients with CLL, immunoblastic transformation of CLL in one, refractory PLL in three, and refractory NHL in three patients.
  • Treatment consisted of fludarabine 30mg/m2 (days 1-3), ara-C 0.5g/m2 (days 3-4), cyclophosphamide 250 mg/m2 (days 2-4), cisplatin 15 mg/m2 IV CI (days 1-4) with GM-CSF 250 microg/m2 from day 5 to recovery of neutrophils and antibiotic prophylaxis.
  • Patients with response were to receive a maximum of six cycles of therapy.
  • One (3%) patient developed cardiac failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoproliferative Disorders / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Female. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - C Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153163.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Ladrière M, Bibes B, Rabaud C, Delaby P, May T, Canton P: [Varicella zoster virus infection after bone marrow transplant. Unusual presentation and importance of prevention]. Presse Med; 2001 Jul 7-13;30(23):1151-4
MedlinePlus Health Information. consumer health - Shingles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Infection par le virus varicelle-zona après greffe de moelle osseuse. Présentations inhabituelles et intérêt de la prophylaxie.
  • Three months after discontinuing VZV prophylaxis, VZV transverse myelitis was diagnosed, leading to death despite prompt treatment with acyclovir.
  • The second patient was a 42-year-old woman treated with autologous bone marrow transplantation for lymphoma.
  • She developed acute viral pancreatitis one month after discontinuing VZV prophylaxis.
  • Recovery was achieved with intravenous treatment.
  • [MeSH-major] Bone Marrow Transplantation. Herpes Zoster / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphoma, Large-Cell, Immunoblastic / therapy. Myelitis, Transverse / diagnosis. Opportunistic Infections / diagnosis. Pancreatitis / diagnosis
  • [MeSH-minor] Adult. Antiviral Agents / administration & dosage. Antiviral Agents / adverse effects. Drug Therapy, Combination. Fatal Outcome. Female. Graft vs Host Disease / drug therapy. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Lymphocyte Depletion. Magnetic Resonance Imaging. Male. Spinal Cord / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505833.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


34. Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A: Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol; 2010 Dec 1;28(34):e704-8
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Boronic Acids / therapeutic use. HIV Infections / complications. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bortezomib. Cytarabine / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dexamethasone / administration & dosage. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Recombinant Proteins. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823416.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Organoplatinum Compounds; 0 / Pyrazines; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; B76N6SBZ8R / gemcitabine; F0P408N6V4 / lenalidomide; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


35. Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H: AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol; 2009 Jun;82(6):490-2
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib.
  • [MeSH-major] Boronic Acids / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Bortezomib. Humans. Lymphoma, Large B-Cell, Diffuse. Lymphoma, Large-Cell, Immunoblastic. Male. Remission Induction. Shock, Septic

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220417.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


36. Yin WH, Zhang HY, Li XF, Ma Y: [Drug-induced lymphadenitis]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):192-4
Hazardous Substances Data Bank. SULFASALAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug-induced lymphadenitis].
  • [MeSH-major] Drug Hypersensitivity / etiology. Drug Hypersensitivity / pathology. Lymphadenitis / chemically induced. Lymphadenitis / pathology. Sulfasalazine / adverse effects
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antigens, CD3 / metabolism. Antigens, CD30 / metabolism. Colitis, Ulcerative / drug therapy. Diagnosis, Differential. Female. Gastrointestinal Agents / adverse effects. Gastrointestinal Agents / therapeutic use. Humans. Immunoblastic Lymphadenopathy / metabolism. Immunoblastic Lymphadenopathy / pathology. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / pathology. Receptors, Complement 3d / metabolism

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450768.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / Gastrointestinal Agents; 0 / Receptors, Complement 3d; 3XC8GUZ6CB / Sulfasalazine
  •  go-up   go-down


37. Rodríguez M, Perea J, Ortega I, Turégano F: [Group A beta-hemolytic Streptococcus necrotizing fascitis secondary to muscular effort]. Enferm Infecc Microbiol Clin; 2002 Jan;20(1):42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease Susceptibility. Humans. Imipenem / therapeutic use. Lymphoma, Large-Cell, Immunoblastic / complications. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / surgery. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11820983.001).
  • [ISSN] 0213-005X
  • [Journal-full-title] Enfermedades infecciosas y microbiología clínica
  • [ISO-abbreviation] Enferm. Infecc. Microbiol. Clin.
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 71OTZ9ZE0A / Imipenem
  •  go-up   go-down


38. Malone KS, Wiggers TB, Spence LM: Monoclonal anti-CD 20 antibody used in non-Hodgkin's lymphoma: a case study. Clin Lab Sci; 2004;17(4):197-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal anti-CD 20 antibody used in non-Hodgkin's lymphoma: a case study.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large-Cell, Immunoblastic / diagnosis. Lymphoma, Large-Cell, Immunoblastic / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / isolation & purification. Humans. Rituximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15559723.001).
  • [ISSN] 0894-959X
  • [Journal-full-title] Clinical laboratory science : journal of the American Society for Medical Technology
  • [ISO-abbreviation] Clin Lab Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement